Pimicotinib: 10 Key Facts on the New Pill for Tenosynovial Giant Cell Tumour

FDA approval of pimicotinib (Pimjetmi) on 10 November 2026 for symptomatic tenosynovial giant cell tumour (TGCT): what TGCT is, the MANEUVER trial results, side effects and liver monitoring.

·

·

8–12 minutes

·

Edited by Joshua Adebanjo, RN

Pimicotinib: New Pill for TGCT Joint Tumours

The US Food and Drug Administration (FDA) has approved pimicotinib, sold as Pimjetmi, a once-daily pill for adults with symptomatic tenosynovial giant cell tumour (TGCT) when surgery could worsen joint function or cause serious complications.

The approval was granted on 10 November 2026. TGCT is a rare, usually non-cancerous tumour that grows in the lining of joints, tendon sheaths and bursae, most often in the knee, hip, ankle or hand, causing pain, swelling and stiffness. It often returns after surgery. In the phase 3 MANEUVER trial, 54% of people taking pimicotinib had their tumours shrink significantly by week 25, compared with 3% on placebo. Pimicotinib is the third medicine of its type, CSF-1R inhibitors, approved in the US for TGCT.

pimicotinib

Imagine a 36-year-old physiotherapist whose knee began swelling and aching five years ago. Scans showed a tenosynovial giant cell tumour. She had two operations, but the tumour came back each time, and her knee is now stiff, painful and difficult to bend. A third operation risks further damage. Her orthopaedic nurse explains that a new once-daily pill has been approved in some countries for people in her situation, targeting the signal that drives the tumour’s growth. She’ll need regular liver blood tests, but it could ease her pain and stiffness without more surgery.

What happened

On 10 November 2026, the FDA approved pimicotinib (Pimjetmi) for adults with symptomatic TGCT for whom surgical resection could potentially cause worsening functional limitation or severe morbidity.

Pimicotinib was developed by Abbisko Therapeutics and is marketed in the US by EMD Serono. It was approved in China in December 2025.

Pimicotinib is the third colony-stimulating factor 1 receptor (CSF-1R) inhibitor approved in the US for TGCT, after pexidartinib (Turalio) and vimseltinib (Romvimza).

10 key facts

  1. The FDA approved pimicotinib (Pimjetmi) on 10 November 2026.
  2. It treats symptomatic tenosynovial giant cell tumour (TGCT).
  3. It is for people in whom surgery could worsen joint function.
  4. Pimicotinib is a once-daily pill.
  5. It blocks CSF-1R, a protein driving tumour growth.
  6. In the MANEUVER trial, 54% responded vs 3% on placebo.
  7. 92% of patients had some tumour shrinkage.
  8. Pain, stiffness and movement also improved.
  9. Liver monitoring is required.
  10. It is the third CSF-1R inhibitor approved for TGCT in the US.

The numbers at a glance

  • Approved: 10 November 2026
  • Response rate at week 25: 54% (34 of 63) vs 3% (1 of 31)
  • 92.1% had some tumour shrinkage
  • 41.3% had responded by week 13
  • All five key secondary endpoints met
  • 8% needed a dose reduction; 2% stopped due to side effects
  • Approved in China in December 2025

What is tenosynovial giant cell tumour?

Tenosynovial giant cell tumour is a rare tumour that develops in the synovium, the thin lining of joints, tendon sheaths and bursae. It is usually benign, meaning it doesn’t spread to other organs, but it can grow and damage the joint.

There are two main forms. The localised form is a single nodule, often in the hand or wrist. The diffuse form spreads through the joint lining, most often in the knee or hip, and is harder to remove completely.

Symptoms include joint swelling, pain, stiffness, reduced movement and sometimes locking. TGCT is caused by a genetic change in some cells that leads to overproduction of CSF-1, which attracts other cells and causes the tumour to grow.

Why this matters

Surgery is the main treatment for TGCT, but the diffuse form often comes back, sometimes several times. Repeated operations can damage the joint, cause stiffness and lead to joint replacement at a young age.

Oral treatments that target CSF-1R offer a non-surgical option to shrink tumours and relieve symptoms when surgery isn’t a good choice.

Having more than one approved CSF-1R inhibitor gives patients and clinicians options with different safety profiles.

What officials and experts said

Coverage of the approval described pimicotinib as ‘a once-daily oral pill’ that ‘gives patients with symptomatic TGCT another option when surgery could cause more harm than good’.

What this means for you

  • If you have TGCT that has returned or is hard to operate on, ask about CSF-1R inhibitors.
  • Ask whether pimicotinib is available where you live.
  • You will need regular liver blood tests during treatment.
  • Report itching, rash, swelling around the eyes or face, and tiredness.
  • Use effective contraception if advised.
  • Continue physiotherapy to protect joint function.

What this means for nurses and health workers

Orthopaedic, oncology and rheumatology nurses help patients weigh surgery against medicine and monitor treatment safely.

  • Explain how CSF-1R inhibitors work.
  • Arrange liver function monitoring.
  • Manage skin and swelling side effects.
  • Counsel on contraception.
  • Support physiotherapy.
  • Track symptoms such as pain and stiffness.

The global picture

TGCT is rare, affecting a small number of people per million each year. Access to CSF-1R inhibitors varies between countries, and many people rely on surgery.

Side effects and warnings

Common side effects, affecting more than one in five people, included itching, rash, swelling of the face and around the eyes, tiredness, nausea, headache and limb swelling. Blood tests may show raised muscle enzymes (CPK), LDH, liver enzymes, lipase, amylase and cholesterol. The label warns of liver toxicity and harm to an unborn baby, and notes that creatinine can rise without kidney damage. In the trial, 8% needed a dose reduction and 2% stopped because of side effects.

The MANEUVER trial

In the phase 3 MANEUVER trial, patients received pimicotinib or placebo. At week 25, 54% of pimicotinib patients had a significant tumour response, compared with 3% on placebo. One patient had a complete response. Improvements were also seen in pain, stiffness, range of motion, physical function and tumour volume.

Surgery or medicine?

Localised TGCT is often cured with surgery. Diffuse TGCT or recurrent tumours near important structures may be better treated with medicine. The decision depends on location, size, symptoms and patient preferences.

Living with TGCT

Physiotherapy, pain management and joint protection help people stay active. Support groups connect people with this rare condition.

Other CSF-1R inhibitors

Pexidartinib and vimseltinib are also approved in the US for TGCT. Each has different side effects and monitoring requirements.

What happens if treatment stops?

Some tumours may grow again after stopping treatment. Your team will discuss how long to continue.

Your care team will review scans and symptoms regularly to decide whether treatment should continue, pause or change, taking into account how you feel and what matters most to you.

Getting the right diagnosis

Because tenosynovial giant cell tumour is rare and its symptoms resemble more common joint problems, such as arthritis, ligament injuries or cysts, diagnosis is sometimes delayed for years. People may be treated repeatedly for sprains or arthritis before an MRI scan reveals the tumour. Clues include swelling and pain in one joint without injury, recurrent bleeding into the joint, or symptoms that keep returning despite treatment. MRI is the most useful imaging test, and a biopsy can confirm the diagnosis. Being seen in a centre experienced in rare joint tumours helps ensure accurate diagnosis and the right balance of surgery, medicine and rehabilitation.

Bring your scan reports to every appointment.

Protecting the joint during and after treatment

Whether treated with surgery, medicine or both, a joint affected by tenosynovial giant cell tumour needs ongoing care. Physiotherapists can design exercises to maintain range of motion, strengthen surrounding muscles and improve balance, which protects the joint and reduces pain. Low-impact activities such as swimming, cycling and walking are often well tolerated. Using ice or heat, pacing activities, and maintaining a healthy weight reduce strain on weight-bearing joints such as the knee and hip. If swelling, locking or pain suddenly worsens, report it, as this can signal tumour growth or bleeding into the joint. Long-term follow-up with MRI scans helps monitor the tumour over time.

Taking an oral treatment every day

Pimicotinib is taken once a day, which many people find convenient, but daily treatment can be hard to keep up over months. Setting a phone reminder, linking the dose to a daily routine, and using a pill organiser can help. Don’t double up on missed doses without advice, and tell your team before starting any new medicines, supplements or herbal remedies. Keeping a simple diary of symptoms and side effects makes follow-up appointments more productive.

Myths and facts

Myth: TGCT is cancer that spreads.
Fact: It is usually benign and rarely spreads.

Myth: Surgery always cures TGCT.
Fact: Diffuse TGCT often returns after surgery.

Myth: Joint swelling is always arthritis.
Fact: Persistent swelling in one joint may need imaging.

Myth: Pills can’t treat joint tumours.
Fact: CSF-1R inhibitors can shrink TGCT.

Questions and answers

What is pimicotinib?

A once-daily pill for TGCT.

How does it work?

It blocks CSF-1R, which drives tumour growth.

How effective was it?

54% responded by week 25 vs 3% on placebo.

What are the side effects?

Itching, rash, facial swelling and tiredness, among others.

Do I need blood tests?

Yes, especially to check the liver.

Is TGCT cancer?

It is usually benign.

Is pimicotinib available outside the US?

It is approved in China; other countries may follow.

What happens next

Regulators in other countries may review pimicotinib. Longer-term data will show how durable responses are and how best to use CSF-1R inhibitors alongside surgery.

Key takeaways

  • The FDA approved pimicotinib (Pimjetmi) on 10 November 2026.
  • It is for people in whom surgery could worsen joint function.
  • It blocks CSF-1R, a protein driving tumour growth.
  • 92% of patients had some tumour shrinkage.
  • Liver monitoring is required.
  • It is the third CSF-1R inhibitor approved for TGCT in the US.

How we report health news

Nursing Media Network reports health news using official sources such as the World Health Organization, national public health agencies, medicines regulators and peer-reviewed research, which are linked at the end of each story. Figures in fast-moving stories, such as outbreaks, change quickly, so we state the date each number refers to. If you are reading this later, check the latest update from the official source before making decisions.

News reports describe what has happened across a population. They cannot tell you what is right for your own health. If a story raises questions about your treatment, symptoms or risk, speak to your nurse or healthcare provider before making any changes.

Staying informed without feeling overwhelmed

A constant stream of health headlines can leave people anxious or confused. It can help to choose one or two trusted sources and check them at set times, rather than scrolling throughout the day. Focus on what you can control, such as vaccinations, regular check-ups, healthy routines and knowing when to seek care. Talk about worries with family, friends or your nurse rather than keeping them to yourself, and take a break from news if it is affecting your sleep or mood. Being informed is useful; being overwhelmed is not.

Finding reliable health information

Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.

If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.

Questions to ask your nurse or healthcare provider

  • Is my TGCT localised or diffuse?
  • Is surgery or medicine better for me?
  • Would pimicotinib be suitable?
  • How will my liver be monitored?
  • What side effects should I watch for?
  • How long would I take it?

But isn’t surgery the only way to remove a joint tumour?

Surgery is often best for localised TGCT, but for recurrent or diffuse tumours, pills like pimicotinib can shrink the tumour and ease symptoms.

Your next step: If a joint tumour keeps coming back after surgery, ask your specialist team whether a CSF-1R inhibitor such as pimicotinib could help.

Related: Knee pain · Osteoarthritis · Soft tissue sarcoma · Joint pain

Sources: CURE, 10 November 2026; FDA: novel drug approvals 2026.

Joshua Ibukunoluwa Adebanjo

Founder & Editor-in-Chief

Joshua Ibukunoluwa Adebanjo

RN, RM, RPHN, BNSc (Obafemi Awolowo University)

Joshua is a registered nurse, midwife and public health nurse with clinical experience at Obafemi Awolowo University Teaching Hospitals Complex. He founded Nursing Media Network to give nurses worldwide trustworthy news, career guidance and a stronger public voice, and leads its editorial direction.

Full profile · Editorial policy · joshuadebanjo.com

Health information on Nursing Media Network is for education and does not replace advice from your own nurse or healthcare provider.

Leave a Reply

Most read

Discover more from Nursing Media Network

Subscribe now to keep reading and get access to the full archive.

Continue reading